BNM-III-170

CD4 mimetic (CD4mc) compound for enhancing HIV vaccine efficacy

Also Known As:

N1-(4-chloro-3-fluorophenyl)-N2-((1R,2R)-2-(guanidinomethyl)-5-((methylamino)methyl)-2,3-dihydro-1H-inden-1-yl) oxalamide

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Abrams, Cameron F: 1 article (11/2021)
2.	Anang, Saumya: 1 article (11/2021)
3.	Chen, Junhua: 1 article (11/2021)
4.	Fritschi, Christopher J: 1 article (11/2021)
5.	Hendrickson, Wayne A: 1 article (11/2021)
6.	Liang, Shuaiyi: 1 article (11/2021)
7.	Madani, Navid: 1 article (11/2021)
8.	Mohammadi, Mohammadjavad: 1 article (11/2021)
9.	Moraca, Francesca: 1 article (11/2021)
10.	Smith, Amos B: 1 article (11/2021)

1.	Infections 01/01/2022 - "CD4mcs like BNM-III-170 inhibit HIV-1 infection by competing with CD4 and by prematurely activating Env, leading to irreversible inactivation. " 11/11/2021 - "The design and synthesis of butyl chain derivatives at the indane ring 3-position of our lead CD4-mimetic compound BNM-III-170 that inhibits human immunodeficiency virus (HIV-1) infection are reported. "